PEGASUS BIOLOGICS RECEIVES FDA APPROVAL TO MARKET ORTHADAPT BIOIMPLANTS

Pegasus Biologics, Inc. developers of novel bioimplants using proprietary technologies announced that the FDA has granted a 510K for the OrthADAPT(TM) Bioimplant, an intelligent, adaptable biologic scaffold which fortifies and promotes tissue remodeling while retaining long-term strength. This grants Pegasus Biologics clearance to market its bioimplants to reinforce compromised soft tissues in sports medicine, orthopedic, and spine applications.

Yahoo News (http://biz.yahoo.com/bw/050816/165361.html?.v=1)